Quantcast

Latest Cyclacel Stories

2014-08-21 16:24:50

ENSPIRIT Trial to Continue as Planned Following Completion of the First of Two Interim Futility Analyses BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 21, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC) based upon completion of the...

2014-08-20 23:02:19

New research report “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, the NSCLC Market in top 8 developed nations is predicted to see a 6.6% CAGR through 2020. London, UK (PRWEB) August 20, 2014 The non-small cell lung cancer (NSCLC) market value is expected to increase considerably in the offing...

2014-07-01 16:25:09

LONDON, July 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/drug_discovery/nasopharyngeal_cancer_global_clinical_trials_review_h1_2014.html Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014 SummaryGlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Nasopharyngeal...

2014-06-10 08:31:13

Study Meets Pre-Specified CR/CRi Rate in First Nine Patients SAN DIEGO, June 10, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced preliminary response data from the first stage of a two-stage, open-label Phase II clinical study of its investigational drug candidate Pracinostat in combination with Vidaza(®) (azacitidine) in elderly patients with newly diagnosed acute myeloid...

2014-05-22 16:26:35

The Leukemia & Lymphoma Society and Oregon Health & Sciences University forged Beat AML collaboration to find effective therapies for acute myeloid leukemia patients WHITE PLAINS, N.Y., May 22, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced a $4 million commitment by the Harry T. Mangurian, Jr. Foundation to support a groundbreaking collaboration between LLS and with Brian Druker, M.D., of Oregon Health and Science University to "Beat...

2014-05-02 08:24:18

SANTA ROSA, Calif., May 2, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for its lead drug candidate RUT58-60. The Company plans to initiate its combined Phase 1/2...

2014-04-09 12:31:42

Initiating Phase Ib studies in NSCLC and AML in 2014 BERGEN, Norway, April 9, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that results from its successful Phase Ia clinical study for lead compound, BGB324, was presented at the American Association of Cancer Research annual conference, which took place on April 5-9, 2014. BGB324 is a first-in-class, highly selective small molecule inhibitor...

2014-04-03 12:29:29

Poor Efficacy and Physicians' Desire for Personalized Therapeutics Will Provide Opportunity for Developers of New Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 3, 2014 /PRNewswire/ -- Decision Resources Group finds that azacitidine (Celgene's Vidaza, generics) will continue to be the patient share leader in treatment of myelodysplastic syndromes (MDS) in the United States and major European markets during the 2013-2023 study period. According to...

2014-03-20 16:26:39

Quizartinib Phase 3 Trial Expected to Begin in Second Quarter 2014 SAN DIEGO, March 20, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced fourth quarter and full-year operating results for 2013. The company will host a conference call today to discuss financial results for the fourth quarter and full-year 2013, and to...

2014-02-28 08:25:51

SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML). (Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO) "We are very pleased to receive this orphan drug...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related